3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Phase 3
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Multiple Myeloma
39
Neoplasms, Plasma Cell
13
Lymphoma
12
Neuroblastoma
10
Leukemia, Myeloid, Acute
10
Lymphoma, Large B-Cell, Diffuse
9
Immunoglobulin Light-chain Amyloidosis
8
Lymphoma, Non-Hodgkin
6
Myelodysplastic Syndromes
5
Lymphoma, Large-Cell, Immunoblastic
5
Lymphoma, Follicular
5
Uveal Melanoma
3
Precursor Cell Lymphoblastic Leukemia-Lymphoma
3
Neoplasms
3
Melanoma
3
Lymphoma, Mantle-Cell
3
Leukemia
3
Amyloidosis
3
Neoplasm Metastasis
2
Hodgkin Disease
2
Ganglioneuroblastoma
2
Venentoclax
1
Smoldering Multiple Myeloma
1
Sarcoma, Ewing
1
Sarcoma
1
Retinoblastoma
1
Rectal Neoplasms
1
Ovarian Neoplasms
1
Neuroectodermal Tumors, Primitive, Peripheral
1
Neoplasms by Histologic Type
1
Interventions
ponatinib
2
napabucasin
2
Irinotecan
2
Imatinib Mesylate
2
Gemcitabine
2
130-nm albumin-bound paclitaxel
2
pralsetinib
1
pembrolizumab
1
nilotinib
1
linifanib
1
ibritumomab tiuxetan
1
bosutinib
1
Vorinostat
1
Temozolomide
1
Sorafenib
1
Rituximab
1
Pemetrexed
1
Paclitaxel
1
Melphalan
1
Leucovorin
1
Fluorouracil
1
FANG vaccine
1
Etoposide
1
Cytarabine
1
Cisplatin
1
Carmustine
1
Carboplatin
1
Bortezomib
1
Bevacizumab
1
BID protein, human
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Neoplasms by Histologic Type
×
Melphalan
×
Clear all
NCT02366663
2018-03-12
SPINOZA
City of Hope Medical Center
Phase 3
Terminated
3 enrolled
8 charts